|
May 9
|
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 8
|
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
|
|
May 1
|
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
|
|
Apr 10
|
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
|
|
Apr 8
|
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
|
|
Mar 28
|
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
|
|
Mar 28
|
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
|
|
Mar 26
|
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
|
|
Mar 18
|
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
|
|
Mar 13
|
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
|
|
Feb 28
|
Q4 2023 Syndax Pharmaceuticals Inc Earnings Call
|
|
Feb 27
|
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
|
|
Feb 26
|
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
|
|
Jan 9
|
Biotech Is Ripe for M&A. These May Be the Next Acquisition Targets.
|
|
Jan 2
|
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
|
|
Dec 23
|
With 85% ownership of the shares, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is heavily dominated by institutional owners
|
|
Dec 19
|
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|
|
Dec 10
|
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
|
|
Dec 5
|
12 Most Promising Stocks to Buy According to Hedge Funds
|